Tucson, Arizona-based ImaRx, a firm that develops biopharmaceuticals for treating vascular disorders, has filed for an IPO. The firm said that it is looking to raise up to $25.87M in an IPO on the NASDAQ Capital Market under the symbol "IMRX", in a filing with the SEC Friday. The IPO is being underwritten by Maxim Group LLC. The firm is backed by Edson Moore Healthcare Ventures. The filing comes after a withdrawal last year of the firm's IPO, where it cited unfavorable market conditions.